Other Viruses Citation List: November 8 - November 21, 2013
Hepatitis C Virus
1. Conformation-based Restrictions and Scaffold Replacements in the Design of Hepatitis C Virus Polymerase Inhibitors: Discovery of Deleobuvir (BI 207127). Laplante, S.R., M. Bos, C. Brochu, C. Chabot, R. Coulombe, J.R. Gillard, A. Jakalian, M. Poirier, J. Rancourt, T. Stammers, B. Thavonekham, P.L. Beaulieu, G. Kukolj, and Y.S. Tsantrizos. Journal of Medicinal Chemistry, 2013. [Epub ahead of print]; PMID[24159919].
[PubMed] OV_1108-112113.
2. Ligand Bioactive Conformation Plays a Critical Role in the Design of Drugs That Target the Hepatitis C Virus NS3 Protease. Laplante, S.R., H. Nar, C.T. Lemke, A. Jakalian, N. Aubry, and S.H. Kawai. Journal of Medicinal Chemistry, 2013. [Epub ahead of print]; PMID[24144444].
[PubMed] OV_1108-112113.
3. Imidazopyridazine Hepatitis C Virus Polymerase Inhibitors. Structure-Activity Relationship Studies and the Discovery of a Novel, Traceless Prodrug Mechanism. Leivers, M.R., J.F. Miller, S.A. Chan, R. Lauchli, S. Liehr, W. Mo, T. Ton, E.M. Turner, M. Youngman, J.G. Falls, S. Long, A. Mathis, and J.T. Walker. Journal of Medicinal Chemistry, 2013. [Epub ahead of print]; PMID[24224729].
[PubMed] OV_1108-112113.
4. Total Synthesis and anti-Hepatitis C Virus Activity of MA026. Shimura, S., M. Ishima, S. Nakajima, T. Fujii, N. Himeno, K. Ikeda, J. Izaguirre-Carbonell, H. Murata, T. Takeuchi, S. Kamisuki, T. Suzuki, K. Kuramochi, K. Watashi, S. Kobayashi, and F. Sugawara. Journal of the American Chemical Society, 2013. [Epub ahead of print]; PMID[24251365].
[PubMed] OV_1108-112113.
Kaposi
5. Combination of Arsenic and Interferon-alpha Inhibits Expression of KSHV Latent Transcripts and Synergistically Improves Survival of Mice with Primary Effusion Lymphomas. El Hajj, H., J. Ali, A. Ghantous, D. Hodroj, A. Daher, K. Zibara, C. Journo, Z. Otrock, G. Zaatari, R. Mahieux, M. El Sabban, A. Bazarbachi, and R. Abou Merhi. Plos One, 2013. 8(11): p. e79474; PMID[24250827].
[PubMed] OV_1108-112113.
SIV
6. Equine Tetherin Blocks Retrovirus Release and Its Activity Is Antagonized by Equine Infectious Anemia Virus Envelope Protein. Yin, X., Z. Hu, Q. Gu, X. Wu, Y.H. Zheng, P. Wei, and X. Wang. Journal of Virology, 2013. [Epub ahead of print]; PMID[24227834].
[PubMed] OV_1108-112113.
Herpes Simplex Virus 1
7. Evaluation of PD 404,182 as an anti-HIV and anti-HSV Microbicide. Chamoun-Emanuelli, A.M., M. Bobardt, B. Moncla, M.K. Mankowski, R.G. Ptak, P. Gallay, and Z. Chen. Antimicrobial Agents and Chemotherapy, 2013. [Epub ahead of print]; PMID[24217696].
[PubMed] OV_1108-112113.
Citations from the ISI Web of Knowledge Listings for O.V.
8. MicroRNA-specific Argonaute 2 Protein Inhibitors. Schmidt, M.F., O. Korb, and C. Abell. ACS Chemical Biology, 2013. 8(10): p. 2122-2126; ISI[000326121400003].
[WOS] OV_1108-112113.
9. Estimation of Efficiency of Solvent-detergent Method for Virus Inactivation in the Technology of Immunoglobulin Production on the Model of Duck Hepatitis B Virus. Zubkova, N.V., V.V. Anastasiev, K.K. Kyuregyan, M.I. Mikhailov, A.K. Lobastova, and I.V. Krasil'nikov. Bulletin of Experimental Biology and Medicine, 2013. 155(6): p. 821-824; ISI[000326114500031].
[WOS] OV_1108-112113.